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Abstract
Introduction: Several studies have examined the effect of genetic variants in genes involved in the estrogen
metabolic pathway on mammographic density, but the number of loci studied and the sample sizes evaluated
have been small and pathways have not been evaluated comprehensively. In this study, we evaluate the
association between mammographic density and genetic variants of the estrogen metabolic pathway.
Methods: A total of 239 SNPs in 34 estrogen metabolic genes were studied in 1,731 Swedish women who
participated in a breast cancer case-control study, of which 891 were cases and 840 were controls. Film
mammograms of the medio-lateral oblique view were digitalized and the software Cumulus was used for
computer-assisted semi-automated thresholding of mammographic density. Generalized linear models controlling
for possible confounders were used to evaluate the effects of SNPs on mammographic density. Results found to
be nominally significant were examined in two independent populations. The admixture maximum likelihood-
based global test was performed to evaluate the cumulative effect from multiple SNPs within the whole metabolic
pathway and three subpathways for androgen synthesis, androgen-to-estrogen conversion and estrogen removal.
Results: Genetic variants of genes involved in estrogen metabolism exhibited no appreciable effect on
mammographic density. None of the nominally significant findings were validated. In addition, global analyses on
the overall estrogen metabolic pathway and its subpathways did not yield statistically significant results.
Conclusions: Overall, there is no conclusive evidence that genetic variants in genes involved in the estrogen
metabolic pathway are associated with mammographic density in postmenopausal women.
Introduction
Mammographic breast density is one of the strongest
risk factors for breast cancer. Several studies have
shown that women with extensive dense tissue are at
two to six times higher risk of developing the disease
than women of similar age with lower mammographic
density [1,2]. A strong genetic basis has been suggested
for mammographic density [3]. Twin studies have esti-
mated the heritability of this trait to be between 60 and
6 7 %[ 4 ] .E v i d e n c ef o rag e n e t i ci n f l u e n c ea l s oc o m e s
from other studies on family history, familial aggregation
and segregation analyses [5,6].
Mammographic density is strongly correlated with
hormone exposure profiles of women [7]. Several hor-
monal risk factors for breast cancer have been found to
influence mammographic density in a similar fashion to
their respective associations with risk for the disease [8].
For example, a strong inverse relationship has been
observed between parity on mammographic density [9].
In addition, hormone replacement therapy (HRT) users
and women who have a late first-born child or late
menopause have higher breast densities on average [9].
In view of evidence suggesting an association between
mammographic density and hormone-related factors,
and the fact that estrogen is a strong risk factor for
postmenopausal breast cancer, efforts have been made
to identify underlying genetic determinants of
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oid hormone biosynthesis and metabolism [10-13]. Such
endeavors assume mammographic density to be an
intermediate phenotype for breast cancer. Several genes
involved in hormone-related pathways - such as
HSD3B1 [5,14], COMT [11,14] and ESR1 [15] - have
been suggested to be associated with mammographic
breast density. Findings are inconsistent, however, and
only few candidate genes have been studied at a time.
We recently reported the results of a study evaluating a
total of 239 SNPs in 34 estrogen metabolic genes in
1,596 breast cancer cases and 1,730 population controls
from Sweden, of which the outcome variable was breast
cancer (Low et al., manuscript submitted). No significant
SNP association was evident after correction for multiple
testing, but pathway-based global tests revealed signifi-
cant association evidence for the overall estrogen
metabolic pathway (P = 0.034) and, in particular, the
androgen-to-estrogen conversion subpathway (P =
0.007). In the present study, we comprehensively examine
genetic variation in the estrogen metabolic pathway with
mammographic density. The number of SNPs and genes
studied provides the most extensive coverage to date
with respect to studying mammographic breast density.
Materials and methods
Study subjects
The subjects included in the current study are drawn
from a population-based case-control study of post-
menopausal breast cancer in women born in Sweden
aged 50 to 74 years at the time of enrollment, which
was between 1 October 1993 and 31 March 1995. Con-
trols were randomly selected from the Swedish Total
Population Register and were frequency matched to the
expected age distribution of the cases. Details on data
collection and subjects have been described previously
[16]. The final study group with both mammographic
density and genotype data included 891 breast cancer
cases and 840 controls. Although all women were post-
menopausal at the time of recruitment to the parent
study, a subset of the women (43/1,731) was premeno-
pausal in reference to the date of mammogram.
Approval of the study was given by the ethical review
board at the Karolinska Institutet (Stockholm, Sweden)
and six other ethical review boards in the respective
regions in which the subjects were based, and informed
consent was obtained from each participant.
Validation of SNPs with significant associations was
performed using mammographic density data from two
other studies.
Mammographic density data
The process of collecting mammographic density data in
this study has been described previously [17]. Film
mammograms of the medio-lateral oblique view were
digitized using an Array 2905HD Laser Film Digitizer
(Array Corporation, Tokyo, Japan), which covers a range
of 0 to 4.7 optical density. For controls, the breast side
was randomized. For cases, the side contralateral to the
tumor was used. The density resolution was set at 12-
bit spatial resolution. The Cumulus software used for
the computer-assisted measurement was developed at
the University of Toronto [18]. For each image, a
trained observer (LE) set the appropriate gray-scale
threshold levels defining the edge of the breast and dis-
tinguishing dense from nondense tissue. The software
calculated the total number of pixels within the entire
region of interest and within the region identified as
dense. These values were used to calculate the percen-
tage of the breast area that is dense. A random 10% of
t h ei m a g e sw e r ei n c l u d e da sr e p l i c a t e st oa s s e s st h e
intra-observer reliability, which was high with a Spear-
man rank correlation coefficient of 0.95.
Gene and SNP selection
The process of gene and SNP selection has been
described in detail by Low et al. (manuscript submitted).
A total of 1,007 SNPs were selected from 35 genes and
their 30 kb flanking sequences that code the enzymes
involved in estradiol or estrone metabolism and are
expressed in the breast. These SNPs were genotyped in
92 Swedish control samples to assess linkage disequili-
brium patterns, to select tagging SNPs (tagSNPs) and to
evaluate their coverage.
Haplotypes were reconstructed using the partition-
ligation-expectation-maximization algorithm [19] imple-
mented in the tagSNPs program [20]. A subset of
tagSNPs were selected based on the R
2 coefficient,
which quantifies how well the tagSNP haplotypes pre-
dict the genotype or the number of copies of haplotypes
an individual carries. The performance of tagSNPs in
capturing unobserved SNPs within the genes was evalu-
ated using a SNP-dropping analysis. In brief, each of the
genotyped SNPs was dropped in turn and then tagSNPs
were selected from the remaining SNPs so that their
haplotypes predicted the remaining SNPs with an R
2
value of 0.85. In total, 312 tagSNPs from the 35 genes
were selected for genotyping.
Figure 1 delineates the processes and genes involved
in the androgen synthesis, androgen-to-estrogen conver-
sion and estrogen removal subpathways. The lists of
SNPs corresponding to each subpathway are summar-
ized in Tables S1 to S3 in Additional file 1.
DNA extraction and genotyping
DNA was extracted from 4 ml whole blood using
the QIAamp DNA Blood Maxi Kit (Qiagen, Hilden,
Germany) according to the manufacturer’si n s t r u c t i o n s
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using a standard phenol/chloroform/isoamyl alcohol
protocol. Genotyping was performed using the primer
extension-based assay from Sequenom (San Diego, CA,
USA) according to the manufacturers’ instructions.
DNA samples were randomly assigned to the plates car-
rying positive and negative controls, and all genotyping
results were generated and checked by laboratory staff
unaware of the case-control status. SNPs with a call rate
<85%, minor allele frequency <1% or out of Hardy-
Weinberg equilibrium (P < 0.05/312) were excluded
from further analysis. The genotype concordance was
>99%, suggesting high genotyping accuracy. Overall, 239
tagSNPs from the 34 genes were successfully genotyped
and used in statistical analysis.
Statistical analysis
Linear regression models were fitted, treating percentage
density as an outcome. Models were adjusted for age,
body mass index, menopausal status and HRT. Age was
coded as 0, 1 and 2 for women <50 years, between 50
and 60 years, and >60 years of age, respectively. The
body mass index was treated as a continuous variable.
Menopausal status was determined from the time differ-
ence between the date of menopause and the date on
which the mammogram was taken. HRT was considered
a categorical variable made up of three groups: never
users, past users and current users. The mammographic
density measurements were transformed by the power
of 0.3, yielding an approximately normal distribution.
The genotypes were coded 0, 1 and 2 and treated as
continuous variables.
A likelihood ratio test was performed for each SNP.
Normal quantile-quantile plots were used to examine
the distributions of the -log10-transformed P values. To
assess whether the SNPs associated with breast cancer
risk are the same SNPs as those associated with mam-
mographic density, we used the Spearman’s rank corre-
lation test, evaluating the relationship between odds
ratios corresponding to SNP effects on breast cancer
Figure 1 Subdivision of the estrogen metabolic pathway. The 34 metabolic genes analyzed in the present study are involved in different
steps of the estrogen metabolism. The genes are divided into the three groups involved in androgen synthesis, estrogen synthesis and estrogen
removal for subpathway-based association analysis.
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percentage density. The admixture maximum likelihood-
based global test [21] was performed to evaluate the
cumulative effect on mammographic density from multi-
ple SNPs within the whole metabolic pathway and three
subpathways for androgen synthesis, androgen-to-estro-
gen conversion and estrogen removal. Affection status
for the admixture maximum likelihood analysis was
defined by taking the lowest quantile of all percentage
density measurements as controls and the highest quan-
tile as cases. P values of the admixture maximum likeli-
hood test were obtained via 5,000 permutations.
Software R (v2.8.0) [22] and admixture maximum likeli-
hood [21] were used for data management, quality con-
trol and statistical analyses.
Validation of significantly associated SNPs
SNP associations with mammographic density were vali-
dated in 1,590 women genotyped with the Illumina
HumanHap500 as part of the Cancer Genetic Markers
of Susceptibility Project (CGEMS) [23]. The CGEMS
project is a National Cancer Institute initiative to con-
duct genome-wide association studies to identify genes
involved in breast cancer and prostate cancer. The initial
CGEMS breast cancer scan was designed and funded to
study the main effect of SNP variants on breast cancer
risk in postmenopausal women, and has been completed
[24]. Briefly, the first stage of the project involved a
whole genome scan of 1,145 invasive postmenopausal
breast cancer cases and 1,142 matched controls from
the Nurses’ Health Study nested case-control study [24].
The Nurses’ Health Study was initiated in 1976, when
121,700 US registered nurses aged 30 to 55 returned an
initial questionnaire [25]. During 1989 and 1990, blood
samples were collected from 32,826 women [26]. For
1,590 of these women - of which 806 were breast cancer
cases and 784 were healthy controls - we also had mam-
mographic density measurements.
We collected mammograms as close as possible to the
date of blood collection (1989 to 1990). To assess mam-
mographic density, the craniocaudal (CC) views of both
breasts were digitized at 261 μm/pixel with a Lumysis
85 laser film scanner, which covers a range of 0 to 4.0
optical density. The software for computer-assisted
thresholding was developed at the University of Toronto
[18]. We used the average percentage density of both
breasts for this analysis. This collection has been
described in detail in a previous publication [27]. SNPs
not available on the Illumina HumanHap550 panel were
imputed using MACH [28] based on HapMap Phase II
(release 21a). For the analysis of imputed data, the Pro-
bABEL package from the ABEL set of programs was
used [29]. Percentage density was transformed by the
power of 0.3 to be consistent with the parent study.
This study was approved by the Committee on the Use
of Human Subjects in Research at Brigham and
Women’s Hospital.
The second validation population consisted of a set of
controls from an ongoing breast cancer case-control
study at the Mayo Clinic. Briefly, the Mayo Clinic Breast
Cancer Study is an Institutional Review Board-approved,
clinic-based, case-control study initiated in February
2001 at Mayo Clinic, Rochester, MN, USA. The study
design has been presented previously [30,31]. Clinic
attendance formed the sampling frame for Mayo Clinic
cases and controls. Consecutive cases were women aged
18 years or over with histologically confirmed primary
invasive breast carcinoma and recruited within 6 months
of the date of diagnosis. Cases lived in the six-state
region that defines Mayo Clinic’s primary service popu-
lation (Minnesota, Iowa, Wisconsin, Illinois, North
Dakota, and South Dakota). Controls without prior his-
tory of cancer (other than nonmelanoma skin cancer)
were frequency matched on age (5-year age category),
race and six-state region of residence to cases. Controls
were recruited from the outpatient practice of the Divi-
sions of General Internal Medicine and Primary Care
Internal Medicine at Mayo Clinic, where they were seen
for routine medical examinations.
The present analysis genotyped Caucasian controls
(99% of study participants) enrolled through September
2007, who had mammograms available, representing 995
total controls (76% of total possible controls), of which
783 were postmenopausal. Screening mammograms
were ascertained close to the enrollment date and the
left CC view was digitized on an Array 2905HD Laser
Film Digitizer, which coversar a n g eo f0t o4 . 7o p t i c a l
density. Percentage mammographic density was esti-
mated by an expert reader [32] on the left CC view,
using the same Cumulus software described above [33].
Genotyping was carried out using TaqMan (Applied
Biosystems, Foster City, CA) according to the manufac-
turer’s instructions, using 10 to 20 ng DNA. Primers
and probes were Assay-by Design (Applied Biosystems).
Following PCR amplification, end reactions are read on
the ABI Prism 7900 ht using Sequence Detection Soft-
ware (Applied Biosystems). SNP associations were exam-
ined only in the 783 postmenopausal controls, to be
comparable with the two other populations. The percen-
tage density was transformed by the power of 0.3 to be
consistent with the parent study.
Results
Our dataset consisted of 1,731 postmenopausal women,
of which 981 were breast cancer cases and 840 were
controls (Table 1). Cases and controls differed signifi-
cantly in age at first birth (P = 0.0126), parity (P <
0.0001), family history of breast cancer (P = 0.0002) and
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have higher percentage density (mean ± standard devia-
tion: 16.7 ± 14.3) than controls (14.6 ± 14.0). No signifi-
cant difference was found for age, height, weight, body
mass index, age at menarche, age at menopause or HRT
usage.
T a b l eS 4i nA d d i t i o n a lf i l e2s h o w sal i s to f3 4g e n e s
involved in the estrogen metabolic pathway and the cor-
responding number of SNPs examined for each gene.
References are given for genes that have been examined
in other studies for an association with mammographic
density. Of the 239 SNPs analyzed, 11 SNPs were found
to be significant at the 5% level (Table 2) - of which the
smallest P value was 0.0019. Among six tagSNPs
selected for the gene CYP11A1, five were found to be
significant in the same direction. The associations in the
single SNP analysis were moderate and would not sur-
vive correction for multiple SNP testing. In addition, the
single-SNP P values showed no clear deviation from the
null distribution, representing no association between
SNPs and percentage density (Figure 2; see also Tables
S1 to S3 in Additional file 1). None of the SNPs found
to be nominally significant in our dataset were found to
be significant in the CGEMS validation set (see Table S5
in Additional file 3). A second, independent validation
carried out on the most significantly associated SNP
(rs11638442) located within the CYP11A1 gene in 783
postmenopausal women with mammograms in the
Mayo Clinic Breast Cancer Study yielded a P value of
0.88 (regression coefficient = -0.000507, 95% confidence
interval = -0.07251 to 0.06237).
Since the estrogen metabolic SNPs examined have pre-
viously been associated with breast cancer risk, we
estimated the correlation between regression coeffi-
cients of SNP effects on mammographic density and
the odds ratios of SNP effects on breast cancer risk, in
order to assess whether the SNPs act through mam-
mographic density as an intermediate phenotype for
breast cancer. No significant relationship was found
between SNP effects on breast cancer risk and percen-
tage density (Spearman’s correlation rho = 0.0411, P =
0.5268). Pathway-based multi-SNP association analyses
Table 1 Selected characteristics of subjects
Breast cancer cases (n = 891) Breast cancer controls (n = 840)
Mean SD Mean SD P value
Age (years) 63.0 6.3 63.0 6.3 0.9045
Height (cm) 164.1 5.7 163.6 5.5 0.0766
Weight (kg) 68.9 110 68.8 11.6 0.8153
Body mass index 25.6 3.9 25.6 4.1 0.8420
Age at menarche (years) 13.6 1.4 13.6 1.5 0.6090
Age at first birth (years) 25.4 50 24.8 4.7 0.0126
Parity 1.9 1.2 2.2 1.3 0.0000
Age at menopause (years) 50.3 3.6 50.1 3.9 0.1223
HRT (% ever use) 0.53 0.50 0.2523
Family history (%) 0.15 0.09 0.0002
Percent density 16.7 14.3 14.6 14.0 0.0017
Means and standard deviations (SD) are given for continuous measures, proportions for other variables. P values based on the Welch ttest for independent
samples. HRT, hormone replacement therapy.
Table 2 Significant SNPs in the estrogen metabolic pathway, corresponding regression coefficients and P values
SNP Gene Minor allele MAF n Coefficient SE P value
rs11638442 CYP11A1 C 0.35 1,677 0.0557 0.0212 0.0088
rs16968478 CYP11A1 G 0.17 1,703 0.0575 0.0263 0.0293
rs2279357 CYP11A1 A 0.20 1,699 0.0511 0.0229 0.0260
rs2959003 CYP11A1 A 0.28 1,669 0.0582 0.0224 0.0094
rs2959008 CYP11A1 A 0.30 1,703 0.0475 0.0221 0.0315
rs2066485 HSD17B3 G 0.14 1,703 0.0668 0.0293 0.0230
rs7039978 HSD17B3 A 0.50 1,694 –0.0632 0.0203 0.0019
rs1469908 NQO1 C 0.37 1,695 –0.0472 0.0206 0.0223
rs17268974 STS A 0.22 1,605 0.0503 0.0238 0.0349
rs2270112 STS C 0.34 1,686 –0.0485 0.0208 0.0197
rs707762 STS A 0.40 1,687 0.0435 0.0205 0.0340
P values from a one-degree-of-freedom likelihood ratio test. MAF, minor allele frequency; SE, standard error.
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density and genetic variations in the overall estrogen
metabolic pathway, or any of the related subpathways
(Table 3).
Discussion
Our study suggests there is no appreciable effect
between genetic variants involved in estrogen metabo-
lism and mammographic density. Neither the overall
estrogen metabolic pathway nor the androgen synthesis,
androgen-to-estrogen conversion and estrogen removal
subpathways were found to be significantly associated
with mammographic density. Single SNP markers with
significant associations with mammographic density
were not validated in two independent datasets.
In view of estrogen exposure being a major risk factor
of postmenopausal breast cancer, and mammographic
density being associated with several hormone-related
factors such as body mass index (increased local estro-
gen conversion due to increased fatty tissue), HRT, and
menopausal status, the estrogen metabolic pathway has
been a candidate pathway for the search of genetic var-
iants related to mammographic density. Most of the var-
iants in the candidate breast cancer genes evaluated in
previous studies, however, have been concluded to be
only weak predictors of mammographic density [10].
Association findings have been both supported and con-
tradicted [3]. As Boyd and colleagues have discussed
[34], it is likely that hormone-related factors are respon-
sible for only a small proportion of the wide variation in
mammographic density. In addition, genetic variants
involved in the estrogen metabolic pathway are generally
investigated based on the premise that mammographic
density is an intermediate and heritable risk factor of
breast cancer [4]. There is, however, accumulating evi-
d e n c et h a tm a m m o g r a p h i cd e n s i t ym a yp r e d i s p o s et o
breast cancer risk through components largely indepen-
dent of estrogen metabolism [35-37].
In our study, no correlation was found between the
estimates of SNP effects on breast cancer risk and mam-
mographic density, suggesting that the same SNPs asso-
ciated with breast cancer risk are not directly correlated
with mammographic density. Tamimi and colleagues
reported that mammographic density and circulating sex
steroid levels were independently associated with breast
cancer risk in postmenopausal women [35]. In addition,
Kerlikowske and colleagues found no correlation
between mammographic density and bone mineral den-
sity [36], both of which have been suggested to be
cumulative markers of elevated estrogen exposure. Dite
and colleagues performed a similar study investigating
the overlap between genetic determinants of mammo-
graphic density and bone mineral density, and reported
a null finding [37]. Another finding in Kerlikowske and
colleagues’ study was that although mammographic den-
sity remained strongly associated with elevated breast
cancer risk after adjustment for hormone-related factors,
the effects of bone mineral density did not [36], suggest-
ing that estrogen metabolism plays only a small role in
the effects of mammographic density on breast cancer
risk.
Many studies examining the effects of exogenous
estrogen exposure are in agreement with the view that
estrogen has limited effects on mammographic density.
Very often, the combined estrogen plus progestin regi-
men was found to affect mammographic density more
than the estrogen-only regimen [38-41], suggesting
that progestins and not estrogens are responsible for
increased mammographic density. Interestingly, mam-
mographic density is also known to have no prognostic
bearing on the estrogen receptor status of breast can-
cer tumors [42-44], thus corroborating an estrogen/
estrogen receptor independent link. Another study
conducted by Vachon and colleagues found no
Figure 2 No association between SNPs and percentage density.
-log10 quantile-quantile P value plots from single-SNP trend tests of
239 SNPs in the estrogen metabolism pathway.
Table 3 Global genetic association tests between SNPs in
the estrogen metabolic pathways and mammographic
breast density
Pathway Number of
SNPs
P
heterogeneity
P
trend
a
Whole pathway 239 0.840 0.507
Androgen synthesis 11 0.761 0.763
Androgen to estrogen
conversion
120 0.587 0.715
Estrogen removal 134 0.834 0.872
aP values based on 5,000 permutations.
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production of estrogen in postmenopausal women) on
mammographic density [45], further supporting this
line of rationale.
Strengths of the present study include the large sam-
ple size and extensive coverage of SNPs in the estrogen
metabolic pathway. In a review by Kelemen and collea-
gues, the authors summarized that previous genetic
association studies exploring the relationship between
the estrogen metabolic pathway and mammographic
density had sample sizes ranging from between 232 and
1,260 women [3]. The number of loci involved in the
estrogen metabolic pathway investigated in these studies
was also limited to eight or less [3], while we examined
239 tagSNPs from 34 genes involved in the estrogen
metabolic pathway. A second strength of the present
study is the use of two independent populations for the
validation of the associations found.
A limitation of the presentw o r ki st h a ti ti n c l u d e s
different mammogram views across the different stu-
dies. The main study on Swedish women utilized the
medio-lateral oblique view, while mammograms of the
C G E M Sa n do ft h eM a y oC l i n i cw e r et a k e nu s i n gt h e
CC view. Several studies, however, have shown correla-
tion of densities from the medio-lateral oblique and
CC views [46,47], and have shown that the different
views yield similar associations with breast cancer [32].
In addition, the main focus of this study was on
genetic determinants of mammographic density in
postmenopausal women. Although no strong associa-
tion was observed between SNPs in the estrogen meta-
bolic pathway examined and mammographic density in
postmenopausal women, whether the same lack of
association between common genetic variation in the
estrogen metabolism pathway and mammographic den-
sity is present in premenopausal women remains to be
clarified.
Conclusions
As mammographic density is generally considered an
intermediate phenotype for breast cancer, the identifica-
tion of genes that influence mammographic density
would play an important role in risk prediction of breast
cancer prior to the start of mammography screenings
and shed light on the mechanisms behind breast cancer
carcinogenesis. Overall, therei sn oc o n c l u s i v ee v i d e n c e
that genetic variants in genes involved in the estrogen
metabolic pathway are associated with mammographic
density in postmenopausal women. This knowledge will
be helpful for directing the focus of future studies to
alternative pathways that may be responsible for a larger
bulk of the genetic component of mammographic
density.
Additional file 1: Tables S1 to S3. Table S1 presents a list of SNPs in
the androgen synthesis subpathway and their corresponding regression
coefficients and likelihood ratio test P values. Table S2 presents a list of
SNPs in the androgen to estrogen conversion subpathway and their
corresponding regression coefficients and likelihood ratio test P values.
Table S3 presents a list of SNPs in the estrogen removal subpathway and
their corresponding regression coefficients and likelihood ratio test P
values.
Click here for file
[http://www.biomedcentral.com/content/supplementary/bcr2488-S1.
DOC]
Additional file 2: Table S4. Table S4 presents genes containing
polymorphisms within the estrogen metabolic pathway evaluated in
relation to mammographic density.
Click here for file
[http://www.biomedcentral.com/content/supplementary/bcr2488-S2.
DOC]
Additional file 3: Table S5. Table S5 presents validation results of
significantly associated SNPs in the Nurses’ Health Study (NHS) and the
Mayo Clinic Breast Cancer Study (MBCS).
Click here for file
[http://www.biomedcentral.com/content/supplementary/bcr2488-S3.
DOC]
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